| アブストラクト | Several cases of herpes zoster (HZ) following mRNA COVID-19 vaccination (BNT162b2 and mRNA-1273) have been reported, and the first epidemiological evidence suggests an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID-19 vaccination. We performed disproportionality analyses (case/non-case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID-19 vaccine recipients compared to influenza vaccine recipients and according to patient age. To 30 June 2021, of 716 928 reports with mRNA COVID-19 vaccines, we found 7728 HZ cases. When compared to influenza vaccines, mRNA COVID-19 vaccines were associated with a significantly higher reporting of HZ (reporting odds ratio 1.9, 95% CI 1.8-2.1). Furthermore, we found a reduced risk of reporting HZ among under 40-year-old persons compared to older persons (reporting odds ratio 0.39, 95% CI 0.36-0.41). Mild and infrequent HZ reactions may occur shortly after mRNA COVID-19 vaccination, at higher frequency than reported with influenza vaccination, especially in patients over 40 years old. Further analyses are needed to confirm this risk. |
|---|
| ジャーナル名 | British journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2022/2/18 |
|---|
| 投稿者 | Preta, Laure-Helene; Contejean, Adrien; Salvo, Francesco; Treluyer, Jean-Marc; Charlier, Caroline; Chouchana, Laurent |
|---|
| 組織名 | Departement de Pharmacologie, Centre Regional de Pharmacovigilance, Hopital;Cochin, Paris, France.;Equipe mobile d'infectiologie, Hopital Cochin, Paris, France.;Universite Paris Descartes, Paris, France.;Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology,;Univ. Bordeaux, Bordeaux, France.;CHU de Bordeaux, Service de Pharmacologie Medicale, Centre Regional de;Pharmacovigilance de Bordeaux, Bordeaux, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35174524/ |
|---|
